{
  "id": "mhgap#risk_safety_5cfda37f",
  "content": "DelBello et al., 2022 (4 RCTs in an NMA of efficacy and y Few antipsychotics/mood stabilizers have been\nsafety of second-generation antipsychotic medicines tested in children and adolescents. The medicines\nin youths with bipolar depression) (200); and Ciray mentioned above were the only efficacious ones.\net al., 2020 (11 placebo-controlled pharmacological\n94\n3. Recommendations\ny The systematic review on bipolar depression in medicines should only be given in a case-by-case\nadolescents (DelBello et al., 2022) only identified manner by a specialist carefully balancing efficacy\nstudies for lurasidone, quetiapine, olanzapine– and side-effects.\nfluoxetine combination. Systematic reviews about\nRemarks\nclassical mood stabilizers and antidepressants\nwere not identified. Lurasidone and olanzapine– y There is not enough evidence to recommend the use\nfluoxetine combination significantly improved of psychotropic medicine in adolescents with bipolar\ndepressive symptoms, while quetiapine did not. disorder (current episode depression). Preliminary\nOlanzapine–fluoxetine combination showed evidence suggests that olanzapine–fluoxetine\nmore discontinuation due to adverse effects than combination (very low certainty) and lurasidone\nplacebo (OR = 3.31; 95% CI: 1.08 to 8.75). Lurasidone (high certainty) are effective in reducing bipolar\nwas similar to placebo and quetiapine showed symptoms in adolescents with bipolar disorder\nsignificantly fewer discontinuations than placebo. (current episode depression).",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "screening_cues",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety DelBello et al., 2022 (4 RCTs in an NMA of efficacy and y Few antipsychotics/mood stabilizers have been\nsafety of second-generation antipsychotic medicines tested in children and adolescents. The medicines\nin youths with bipolar depression) (200); and Ciray mentioned above were the only efficacious ones.\net al., 2020 (11 placebo-controlled pharmacological\n94\n3. Recommendations\ny The systematic review on bipolar depression in medicines should only be given in a case-by-case\nadolescents (DelBello et al., 2022) only identified manner by a specialist carefully balancing efficacy\nstudies for lurasidone, quetiapine, olanzapine– and side-effects.\nfluoxetine combination. Systematic reviews about\nRemarks\nclassical mood stabilizers and antidepressants\nwere not identified. Lurasidone and olanzapine– y There is not enough evidence to recommend the use\nfluoxetine combination significantly improved of psychotropic medicine in adolescents with bipolar\ndepressive symptoms, while quetiapine did not. disorder (current episode depression). Preliminary\nOlanzapine–fluoxetine combination showed evidence suggests that olanzapine–fluoxetine\nmore discontinuation due to adverse effects than combination (very low certainty) and lurasidone\nplacebo (OR = 3.31; 95% CI: 1.08 to 8.75). Lurasidone (high certainty) are effective in reducing bipolar\nwas similar to placebo and quetiapine showed symptoms in adolescents with bipolar disorder\nsignificantly fewer discontinuations than placebo. (current episode depression). Delbello et al., 2022 (4 rcts in an nma of efficacy and y few antipsychotics/mood stabilizers have been\nan toàn of second-generation antipsychotic medicines tested in children and adolescents. the medicines\nin youths wit..."
}